Cryosurgery as primary treatment for XXXX .

@entity1 @entity323 @entity263 @entity292 @entity3832 @entity1118 @entity1486
OBJECTIVE: To present the early results of the use of third-generation cryotherapy as primary treatment for @entity263 in China. @entity1 AND METHODS: From January 2006 to December 2009, 102 @entity1 underwent primary cryosurgery for clinically @entity263 . All @entity1 underwent a dual freeze-thaw cycle using third-generation cryotechnology with ultrathin 17-gauge cryoneedles. RESULTS: The @entity1486 (PSA) level for all @entity1 at the last follow-up visit was less than 0.5 ng/ml in 94 @entity1 (92.2%) and 0.5 ng/ml or more in 8 (7.8%). One @entity1 (1.0%) had recurrent @entity263 confirmed by prostate biopsy and was treated with salvage cryotherapy. Seven other @entity1 (6.9%) had an elevated PSA level after cryotherapy despite negative posttreatment biopsies and a metastatic evaluation. Of 102 @entity1 , 1 @entity1 was incontinent preoperatively. Of the remaining 101 @entity1 , 4 @entity1 (4.0%) developed mild incontinence requiring 1 to 2 pads per day. Urethral sloughing occurred in 5 of the 102 @entity1 (4.9%) and in 1 of these @entity1 (1.0%) required transurethral resection of sloughing. The rates of @entity323 were 64.1%. No @entity3832 , @entity292 , @entity1118 was reported. The median inpatient stay after cryoablation was 3.2 days. CONCLUSION: Early results suggest that cryotherapy offers a safe and effective alternative for the primary treatment of @entity263 . Additional studies with longer follow-up are necessary to determine the sustained efficacy of this procedure.
